PLEKHO1

Across TCGA pan-cancer cohorts, PLEKHO1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLEKHO1 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PLEKHO1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLEKHO1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where PLEKHO1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.897	0.993	.005	32	view →
PDAC	OS	Tertile	All	0.607	0.334	.012	31	view →
LSCC	OS	Tertile	III,IV	0.925	0.481	.008	4	view →
CCRCC	OS	Median	IV	0.451	1.000	.016	1	view →
LUAD	OS	Median	II,III,IV	0.894	0.968	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLEKHO1–HNSC (DFS)

Open the HNSC breakdown →